Tag: Clinical Trials

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...

A growing group of companies is developing pharmaceutical-grade psilocybin from mushrooms, creating the infrastructure needed to investigate whether the broader ...

Entropy Neurodynamics has reported sustained improvements in treatment-resistant binge-eating disorder three months after patients received two infusions of its IV ...

Psychedelic medicine has spent the past decade developing clinical evidence almost exclusively in adults. Adolescents have largely remained outside the ...

The UK’s psychedelic sector is moving into a more commercially significant phase, with late-stage clinical programmes, pharmaceutical investment and changes ...

A new executive order could position the US territory as a research destination for emerging psychedelic therapies as clinicians, researchers ...

Australian psychedelic biotechnology company Entropy Neurodynamics (ASX: ENP) has secured Human Research Ethics Committee (HREC) approval to begin what it ...

Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...

LSD has moved a significant step closer to becoming an approved prescription medicine after Definium Therapeutics reported positive topline results ...

While psilocybin and MDMA have dominated the modern psychedelic renaissance, another compound has quietly remained on the sidelines. Ibogaine has ...